Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 8% Improvement Relative Risk Ventilation -2% 7-point scale 22% primary c19early.org/cp Denkinger et al. Conv. Plasma for COVID-19 RCT LATE Favors conv. plasma Favors control
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
Denkinger et al., Nature Cancer, doi:10.1038/s43018-022-00503-w
Denkinger et al., Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and.., Nature Cancer, doi:10.1038/s43018-022-00503-w
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 134 hospitalized patients showing no significant difference in outcomes with convalescent plasma for all patients, however significantly improved mortality and time to improvement was seen for patients with cancer.
risk of death, 8.2% lower, RR 0.92, p = 0.39, treatment 68, control 66, inverted to make RR<1 favor treatment, day 84.
risk of mechanical ventilation, 2.5% higher, RR 1.02, p = 1.00, treatment 19 of 68 (27.9%), control 18 of 66 (27.3%).
risk of 7-point scale, 22.5% lower, HR 0.78, p = 0.22, treatment 68, control 66, inverted to make HR<1 favor treatment, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Denkinger et al., 29 Dec 2022, Randomized Controlled Trial, Germany, peer-reviewed, 54 authors, study period 3 September, 2020 - 20 January, 2022.
Contact: claudia.denkinger@uni-heidelberg.de, carsten.mueller-tidow@med.uni-heidelberg.de.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: nature cancer Article https://doi.org/10.1038/s43018-022-00503-w Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial Received: 16 September 2022 A list of authors and their affiliations appears at the end of the paper Accepted: 29 November 2022 Published online: xx xx xxxx Check for updates Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with high morbidity and mortality. Furthermore, impaired humoral response renders severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines less effective and treatment options are scarce. Randomized trials using convalescent plasma are missing for high-risk patients. Here, we performed a randomized, open-label, multicenter trial (https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE) in hospitalized patients with severe COVID-19 (n = 134) within four risk groups ((1) cancer (n = 56); (2) immunosuppression (n = 16); (3) laboratory-based risk factors (n = 36); and (4) advanced age (n = 26)) randomized to standard of care (control arm) or standard of care plus convalescent/vaccinated anti-SARS-CoV-2 plasma (plasma arm). No serious adverse events were observed related to the plasma treatment. Clinical improvement as the primary outcome was assessed using a seven-point ordinal scale. Secondary outcomes were time to discharge and overall survival. For the four groups combined, those receiving plasma did not improve clinically compared with those in the control arm (hazard ratio (HR) = 1.29; P = 0.205). However, patients with cancer experienced a shortened median time to improvement (HR = 2.50; P = 0.003) and superior survival with plasma treatment versus the control arm (HR = 0.28; P = 0.042). Neutralizing antibody activity increased in the plasma cohort but not in the control cohort of patients with cancer (P = 0.001). Taken together, convalescent/vaccinated plasma may improve COVID-19 outcomes in patients with cancer who are unable to intrinsically generate an adequate immune response. The coronavirus disease 2019 (COVID-19)-associated risk of death is particularly high for patients with hematologic or solid cancer1–3, advanced age4,5 and other conditions6,7. Both humoral8 and cellular9 immunodeficiency contribute to unfavorable outcomes. Despite this, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine availability and waning vaccine efficacy in these patients remain concerning10,11. Few therapies improve outcomes in severe COVID-19 with impaired oxygenation12. Monoclonal antibodies as pre- or postexposure prophylaxis or as early treatment can reduce the risk of severe COVID-19 (refs. 13,14). Evidence for the benefit of monoclonal antibodies in patients requiring oxygen supplementation is missing15 or pending16. e-mail: Claudia.Denkinger@uni-heidelberg.de; carsten.mueller-tidow@med.uni-heidelberg.de Nature Cancer Article https://doi.org/10.1038/s43018-022-00503-w Randomized (n = 134)a Allocation Allocated to plasma (n = 68) - All received the allocated intervention (n = 68) Allocated to standard of care (n = 66) - All received the allocated intervention (n = 66) Follow-up Lost to follow-up (n = 10)b - At day 14 (n = 1) - At day 28 (n = 2) - At day 56 (n = 2) - At day 84 (n = 5) Lost to follow-up (n = 4)b - At day 14 (n = 1) - At day 56 (n = 3) Discontinued intervention (received only one infusion of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit